

Class of Antihypertensive Unimportant if It Works

BY BRUCE JANCIN
Denver Bureau

SNOWMASS, COLO. — Off-heard claims that some antihypertensive agents possess blood pressure-independent cardioprotective effects don't hold up to scrutiny, Dr. Robert A. Vogel said at a conference sponsored by the Society for Cardiovascular Angiography and Interventions.

Indeed, the major lesson to be gleaned from examining the seven big, published,

randomized, class-to-class treatment trials is that in hypertensive patients without heart failure, the key consideration in preventing cardiovascular events is to just lower the blood pressure. Which classes of drugs are employed to reach this goal is not of great importance, according to Dr. Vogel, director of clinical vascular biology at the University of Maryland, Baltimore.

"The point I want to make, and it's critical and yet it's something we often forget, is that treating hypertension is one of the

most rewarding things we can do. For every 1-mm Hg increase in systolic blood pressure, we get a 4% increase in ischemic heart disease events; conversely, we get the same benefit as we drop blood pressure," he said.

"When you look at these seven trials, it doesn't make much sense. I can't look at them and say, 'This is the agent I want for my patients with cardiovascular disease.'"

For one thing, only three of those seven trials even achieved a level playing field by producing equivalent blood pres-

sure reductions in both of the study arms.

In one of the three trials—the Comparison of Amlodipine vs. Enalapril to Limit Occurrence of Thrombosis (CAMELOT) study—the calcium channel blocker proved more effective than the angiotensin-converting enzyme inhibitor for prevention of cardiovascular events.

In the International Verapamil SR/Trandolapril Study (INVEST), the calcium channel blocker-based treatment strategy and β -blocker-based approach proved equally effective for CV risk reduction. And in the Second Australian National Blood Pressure Study, the ACE inhibitor came out ahead of diuretic therapy. So no clear winning strategy emerged from the studies featuring equal lowering of blood pressure.

In contrast, in the four trials in which the blood pressures achieved were unequal, the conclusion in every case was that lower blood pressure provided protection against cardiovascular (CV) events.





The blood pressure differences between study arms were small, typically only 1-3 mm Hg, but in these large studies ranging in size from 9,000 to 33,000 patients, the resultant spread in event rates became statistically significant.

For example, in the 33,257-patient Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALL-HAT), the rates of stroke, heart failure, and combined CV events were significantly lower in patients on diuretics than in those on ACE inhibitors—findings opposite those of the Australian study. The explanation appears to be that in ALL-HAT, the achieved systolic blood pressure in the ACE inhibitor group was 2-mm Hg higher than in the diuretic group.

The story was similar in the other three trials with unequal blood pressure. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, and Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial, the "winning" strategy for CV protection was the one backed by the trial's commercial sponsors—and also the one that resulted in significantly lower blood pressure than the comparator, he said.

What physicians could use now is a way to tell if they've lowered a patient's blood pressure enough, much as C-reactive protein levels are used to see if LDL cholesterol has been reduced enough to decrease CV risk. ■

Brought to you by **sanofi aventis**

<p>THE ECS IMPACTS THE METABOLISM OF LIPIDS AND GLUCOSE¹⁻³</p>	<ul style="list-style-type: none"> ECS overactivity may be associated with the development of cardiometabolic risk factors including: <ul style="list-style-type: none"> Low HDL cholesterol High triglycerides High waist circumference Elevated fasting glucose Insulin resistance 	
<p>THE ECS HELPS REGULATE PHYSIOLOGIC PROCESSES¹⁻⁴</p>	<ul style="list-style-type: none"> The ECS consists of signaling molecules and their receptors, including the cannabinoid receptor CB₁² Endocannabinoids bind to CB₁ receptors and trigger events that may have a negative impact on lipid levels and insulin sensitivity¹ CB₁ receptors are located in sites such as muscle, the liver, the brain, and adipose tissue^{1,2,4,6} 	
	<p>RESEARCH CONTINUES TO INVESTIGATE THE ROLE OF CB₁ RECEPTORS IN MUSCLE*</p>	<ul style="list-style-type: none"> Reduced glucose uptake has been observed in isolated skeletal muscle of genetically obese, insulin-resistant animals
	<p>ENDOCANNABINOIDS TARGET FATTY ACID PRODUCTION IN THE LIVER³</p>	<ul style="list-style-type: none"> May contribute to dyslipidemia and insulin resistance^{3,7}
	<p>PRESENT IN MULTIPLE AREAS OF THE BRAIN²</p>	<ul style="list-style-type: none"> Hypothalamus integrates signals from adipose tissue and other peripheral tissues^{8,9}
	<p>ADIPOSE TISSUE—MORE THAN SIMPLY A FAT STORAGE DEPOT</p>	<ul style="list-style-type: none"> Produces factors active in the metabolism of lipids and glucose¹⁰ Low levels of adiponectin negatively affect glucose and free fatty acids^{1,10}
<p>EXPLORING THE EFFECTS OF THE ECS</p>	<ul style="list-style-type: none"> This newly discovered physiologic system provides new opportunities for understanding cardiometabolic risk 	

*Data from animal model only.

References

- Bensaid M, Gary-Bobo M, Esclançon A, et al. The cannabinoid CB₁ receptor antagonist SR141716 increases Acp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. *Mol Pharmacol*. 2003;63:908-914.
- Harrold JA, Williams G. The cannabinoid system: a role in both the homeostatic and hedonic control of eating? *Br J Nutr*. 2003;90:729-734.
- Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB₁ receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. *J Clin Invest*. 2005;115:1298-1305.
- Domenicali M, Ros J, Fernández-Varo G, et al. Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. *Gut*. 2005;54:522-527.
- Rhee M-H, Bayewitch M, Avidor-Reiss T, Levy R, Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. *J Neurochem*. 1998;71:1525-1534.
- Upham BL, Rummel AM, Carbone JM, et al. Cannabinoids inhibit gap junctional intercellular communication and activate ERK in a rat liver epithelial cell line. *Int J Cancer*. 2003;104:12-18.
- Flier JS, Maratos-Flier E. Obesity. In: Kasper DL, Braunwald E, Fauci AS, et al, eds. *Harrison's Principles of Internal Medicine*. 16th ed. New York, NY: McGraw-Hill; 2005:chap 64. Available at: <http://www.accessmedicine.com/content.aspx?alD=60099&searchStr=obesity>. Accessed December 5, 2005.
- Badman MK, Flier JS. The gut and energy balance: visceral allies in the obesity wars. *Science*. 2005;307:1909-1914.
- Devaskar SU. Neurohumoral regulation of body weight gain. *Pediatr Diabetes*. 2001;2:131-144.
- Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. *J Clin Endocrinol Metab*. 2004;89:2548-2556.

VERBATIM

'What do you think is holding the current health care system together? You. It's the altruism of the physicians of this nation.'

Rep. Tom Price (R-Ga.), on the need for health care reform, p. 71